| | | | | | | | | Sponsored | | Access an evolving library of microorganisms for assay development and analytical studies. Select from available strains or work with our experts on custom growth to support feasibility, LOD, inclusivity, exclusivity, cross-reactivity, and other performance studies. Available in a variety of formats, including non-infectious viral lysates, live and heat inactivated culture fluids, purified DNA, and more. |
|
|
| | |
| |
| | |
|
|
| | | | | | XiFin has published the results of its annual Payor Denial Impact Report, showing a rise in clinical laboratory, molecular diagnostic, and genomics claim denials in 2025. Key findings from the report and summarized in a press release. |
|
|
|
| |
| | |
|
|
| | | | | | Penn Medicine’s Privacy Officer John Nocito recently shared how his team investigates possible improper patient record access across their health system. The process is described in an article by David Raths. originally published by our sister publication, Healthcare Innovation. |
|
|
|
| |
| | |
|
|
| | | | | | Medical Laboratory Observer (MLO) is conducting a series of polls on point-of-care testing (POCT) in clinical laboratories. Tell us: What is the biggest POCT challenge your lab faces? |
|
|
|
| |
| | |
|
|
| | | | | | Sponsored | | Most of what determines how an assay performs is decided before you run your first qPCR reaction, sequence a sample, or build an immunoassay or flow cytometry panel. The Assay Development Handbook covers the pre-analytical decisions that get locked in early and how to make them before they're permanent. |
|
|
| | |
| |
| | |
|
|
| | | | | | Where should molecular infectious disease testing be performed? Join Dr. Kenneth Gavina October 28 for a free CE webinar exploring centralized versus decentralized testing and its impact on workflow, turnaround time, diagnostic performance, and patient care. |
|
|
|
| |
| | |
|
|
| | | | | | Agilent Technologies is set to acquire Proscia in a $240 million cash deal, with potential additional payments based on future milestones, strengthening its digital pathology solutions and long-term growth prospects. |
|
|
|
| |
| | |
|
|
| | |
|
| | |
|